Back

State-of-the-art lecture on new therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension

30 August 2026 (08:15 - 08:33)
Organised by: Logo
Congress Presentation Part of: New therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Christopher B Granger

Duke University Medical Center, Durham (United States of America)

4 More presentations in this session

Presentation thumbnail
RNA interference therapy targeting hepatic angiotensinogen for the treatment of hypertension and cardiovascular disease: a first-in-human and proof-of-concept study
Doctor Y. He (US) Doctor C. O'Donnell (Boston, US)
Abstract Slides Video
Presentation thumbnail
Effects of a novel low-dose triple combination antihypertensive pill on blood pressure, according to background blood pressure medications: results from the TRIDENT trial
Professor A. Rodgers (Sydney, AU)
Abstract Slides Video
Presentation thumbnail
Effect of diuretic dose on baxdrostat efficacy and safety in uncontrolled and resistant hypertension: a post hoc analysis of the BaxHTN trial
Professor B. Williams (London, GB)
Abstract Slides Video
Presentation thumbnail
Adherence to antihypertensive therapy and cardiovascular outcomes: an individual participant data meta-analysis of randomised controlled trials
Miss Q. Yang (Oxford, GB)
Abstract Slides Video

Access the full session

Session thumbnail
New therapeutic strategies targeting renin-angiotensin-aldosterone system in hypertension
Video

The Event

Event poster

ESC Congress 2026

30 August 2026 08:15 CET
You may be interested in
thumbnail
Congress Session
New drugs in the management of hypertension: global perspectives
30 August 2025
thumbnail
Congress Presentation
Third: why comprehensive blockade matters?
29 August 2026
thumbnail
Congress Presentation
RNA-based blood pressure lowering agents
2 September 2024
thumbnail
Congress Presentation
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
30 August 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources